Antiviral Drug Discovery and Development Center - Overall

抗病毒药物发现与开发中心 - 总体

• 批准号: 8641766
• 负责人: RICHARD J. WHITLEY
• 金额: $ 627.07万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-03-01 至 2019-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8641766
• 关键词: Alphavirus; Antiviral Agents; Chemicals; Coronavirus; Development; Evaluation; Flavivirus; Human Resources; Influenza; Lead; Mediating; Names; Pathway interactions; Pharmaceutical Chemistry; Polymerase; Productivity; Research; Research Project Grants; Scientist; Therapeutic; Translational Research; Validation; Viral; Virus Diseases; drug candidate; drug development; drug discovery; high throughput screening; novel; operation; preclinical evaluation; research clinical testing; scaffold; screening; small molecule; success

DESCRIPTION (provided by applicant): The herein proposed Center of Excellence for Translational Research (CETR), which will be named the Antiviral Drug Discovery and Development Center (AD3C) has, at its center, the theme to develop new small molecule therapeutics for emerging and re-emerging viral infections. Translational research will focus on the inhibition of viral replication, especially viral polymerases. Progression pathways will includ target validation, high throughput screening to identify novel chemical scaffolds, and basic virologic research to prove and further probe the exact mechanism of action of identified lead molecules in viral replication. Medicinal chemistry and lead development activities will advance identified compounds down the drug discovery and development pathway, ultimately leading to preclinical evaluation of promising drug candidates for clinical evaluation. The AD3C has four interrelated research projects with a focus on flaviviruses, coronaviruses, alphaviruses and influenza. They will be supported in their efforts by three cores: an Administrative Core (Core A), a Screening Core (SC; Core B) and a Medicinal Chemistry and Lead Development Core (MCLDC; Core C). Organization and interaction between all projects and cores will be mediated out of the Administrative Core, with day to day AD3C operations led by the Core's personnel. An Executive Committee (EC) consisting of all project and core leaders will regularly review the projects' and cores' activities and productivity. Finally, an External Scientific Advisory Board (EAB) of distinguished scientists has been established to annually provide a high level evaluation of AD3C's progress and successes, and aid in refining the Center's activities and direction.

描述（由申请人提供）：本文提出的转化研究卓越中心（CETR），将被命名为抗病毒药物发现和开发中心（AD 3C），其中心主题是开发新的小分子治疗剂用于新发和复发的病毒感染。转化研究将集中在抑制病毒复制，特别是病毒聚合酶。进展途径将包括靶点验证、高通量筛选以鉴定新型化学支架，以及基础病毒学研究以证明并进一步探索已鉴定的先导分子在病毒复制中的确切作用机制。药物化学和先导化合物开发活动将推进已鉴定化合物的药物发现和开发途径，最终导致对有前景的候选药物进行临床前评价。AD 3C有四个相互关联的研究项目，重点是黄病毒、冠状病毒、甲病毒和流感。他们的工作将得到三个核心的支持：行政核心（核心A）， 筛选核心（SC;核心B）和药物化学和电极导线开发核心（MCLDC;核心C）。所有项目和核心之间的组织和互动将在行政核心之外进行调解，日常AD 3C操作由核心人员领导。由所有项目和核心领导人组成的执行委员会将定期审查项目和核心的活动和生产力。最后，成立了一个由杰出科学家组成的外部科学咨询委员会（EAB），每年对AD 3C的进展和成功进行高水平的评估，并帮助完善中心的活动和方向。